MCM2 and ovarian cancer: Deng et al. (2019) reported that knockdown of MCM2 significantly improved the chemoresistance of ovarian cancer to carboplatin and olaparib, indicating that MCM2 may be a promising therapeutic target (Zhong et al., 2018). Recently, MCM2 has been identified as a vital downstream molecule of various oncogenes, such as CAMKK2 and MEK1 (Najar et al., 2021).